Showing results (421-430 of 826) with videos related to

Sort By:
Pageof 83
Neuro-Oncology|August 21, 2015
The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptomsTerri S Armstrong, Elizabeth Vera-Bolanos, Alvina A Acquaye, et al.
Frontiers in Immunology|May 10, 2021
Role of CCR2+ Myeloid Cells in Inflammation Responses Driven by Expression of a Surfactant Protein-C Mutant in the Alveolar EpitheliumAlessandro Venosa, Sophie Cowman, Jeremy Katzen, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2013
Structure of Est3 reveals a bimodal surface with differential roles in telomere replicationTimsi Rao, Johnathan W Lubin, Geoffrey S Armstrong, et al.
World Journal of Gastroenterology|July 5, 2005
Hydrogen sulfide protects colon cancer cells from chemopreventative agent beta-phenylethyl isothiocyanate induced apoptosisPeter Rose, Philip-K Moore, Shen-Han Ming, et al.
Annals of the Royal College of Surgeons of England|January 1, 1993
Will screening for breast cancer reduce mortality? Evidence from the first year of screening in AvonS Nicholson, A J Webb, B Coghlan, et al.
Traffic (Copenhagen, Denmark)|November 4, 2004
Ncr1p, the yeast ortholog of mammalian Niemann Pick C1 protein, is dispensable for endocytic transportShaochong Zhang, Jihui Ren, Hongzhe Li, et al.
Malaria Journal|March 20, 2013
T1BT* structural study of an anti-plasmodial peptide through NMR and molecular dynamicsElena Topchiy, Geoffrey S Armstrong, Katherine I Boswell, et al.
The Journal of Biological Chemistry|April 19, 2014
Residue histidine 50 plays a key role in protecting α-synuclein from aggregation at physiological pHYing-Chih Chi, Geoffrey S Armstrong, David N M Jones, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosaGlenn A Pankuch, Gengrong Lin, Aya Kubo, et al.
Journal of Cancer Research and Clinical Oncology|September 10, 1999
Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancerG T Budd, J Atiba, R T Silver, et al.
Pageof 83